Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-retatrutide-10mg
Retatrutide (10mg)
Ultra High >99.5% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
This groundbreaking triple agonist is transforming weight loss journeys, with clinical trials showing up to 24% body weight reduction in just 48 weeks—results that rival bariatric surgery.
Retatrutide is a long-acting triple agonist that simultaneously targets GLP-1, GIP, and glucagon receptors, delivering unmatched weight loss and metabolic benefits.
By activating three key hormones at once, Retatrutide crushes appetite, ramps up fat burning, and increases energy expenditure—leading to dramatic, sustainable weight loss. The glucagon boost burns calories like exercise—perfect for stubborn fat that won't budge.
Intended Research Use
- Drives massive weight loss (up to 24% in trials)
- Melts visceral fat and improves liver health (82% reduction)
- Boosts insulin sensitivity and energy levels
- Drops HbA1c by ~2% in diabetes
- Improves blood pressure and lipid profiles
menu_bookScientific Publications
N Engl J Med (2023)
Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37366315/
Lancet (2023)
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37364343/
Nat Med (2024)
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/38877164/
Clinical Evidence: Phase 3 trials prove it: participants lost 11–24% body weight over 48 weeks, with many dropping ≥15%—far beyond diet/exercise alone. In type 2 diabetes, it slashed HbA1c by ~2% while shedding ~17kg. The triple action crushes hunger, burns fat faster, and protects your liver.
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
Clinical research suggests combining Retatrutide with complementary peptides can enhance weight management outcomes. These combinations target multiple metabolic pathways for amplified fat-burning effects.
Cagrilintide (5mg vial)
arrow_forwardmyo-cagrilintide-5mg
Supercharges satiety for even faster weight loss through amylin-analog synergy.
AOD-9604 (5mg vial)
arrow_forwardmyo-hgh-fragment-aod-9604-5mg
Targets stubborn fat pockets while Retatrutide handles overall metabolism.
Semaglutide (5mg vial)
arrow_forwardmyo-semaglutide-5mg
Amplifies GLP-1 effects for maximum appetite control and fat burn.
Mazdutide 5mg (5mg vial)
arrow_forwardmyo-mazdutide-5mg
Dual GLP-1/glucagon agonist with similar 20–24% weight loss outcomes — compared with Retatrutide in trials exploring dual vs. triple receptor activation.
Survodutide 10mg (10mg vial)
arrow_forwardmyo-survodutide-10mg
GLP-1/glucagon dual agonist with particular hepatic fat reduction benefits — studied alongside Retatrutide for overlapping appetite regulation mechanisms.
Cycling Note: Once-weekly subcutaneous for minimum 12 weeks (trials up to 48 weeks). Continue for ongoing fat loss results.
